María Belen Noboa-Sevilla

Dr. María Belen Noboa-Sevilla

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2023 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
MNMaría Belen Noboa-Sevilla
María Belen Noboa-Sevilla
FHFernanda Hernández-González
Fernanda Hernández-González
XAXavier Alsina-Restoy
Xavier Alsina-Restoy
NPNancy Pérez-Rodas
Nancy Pérez-Rodas
Jacobo Sellares TorresJacobo Sellares Torres
Jacobo Sellares Torres

1 September 2025 in Journal of Respiration
Verified
Journal Article
Open access
PDF file
MNMaría Belen Noboa-Sevilla
María Belen Noboa-Sevilla
Fernanda HernandezFernanda Hernandez
Fernanda Hernandez
SCSandra Cuerpo
Sandra Cuerpo
XRXavier Alsina Restoy
Xavier Alsina Restoy
NPNancy Pérez-Rodas
Nancy Pérez-Rodas
Jacobo Sellares TorresJacobo Sellares Torres
Jacobo Sellares Torres
Progressive pulmonary fibrosis (PPF) is a clinical syndrome associated with worsening quality of life and increased mortality among patients with various interstitial lung diseases. This review aims to update the concepts and criteria that adequately define PPF, aiming to facilitate earlier recognition and optimize clinical management. Fibrosing interstitial lung disease (ILD-f) can progress over time despite optimal management of the underlying conditions. Current criteria for defining PPF include worsening respiratory symptoms, decline in pulmonary function tests (particularly forced vital capacity and diffusing capacity), and radiographic progression over a 1-year follow-up period. However, implementation of these criteria in clinical practice poses challenges. This review discusses the limitations of current evaluation methods and proposes future directions, including the need for validated symptom assessment tools, standardization of pulmonary function testing, and improvements in quantitative radiological evaluation methods.

1 May 2023
Verified
Conference Paper
Closed access
MNMaría Belen Noboa-Sevilla
María Belen Noboa-Sevilla
WAW.D. Arias
W.D. Arias
Rodrigo Torres-CastroRodrigo Torres-Castro
Rodrigo Torres-Castro
GCG. Cruz-Murillo
G. Cruz-Murillo
HGH. Guaman-Arcos
H. Guaman-Arcos
Jacobo Sellares TorresJacobo Sellares Torres
Jacobo Sellares Torres

1 September 2026 in Respirar
Verified
Journal Article
Open access
PDF file
MBM. Giovanna Binetti-Padilla
M. Giovanna Binetti-Padilla
JZJorge L. Zambrano-Zambrano
Jorge L. Zambrano-Zambrano
ESEfraín J. Sánchez-Angarita
Efraín J. Sánchez-Angarita
MNMaría Belen Noboa-Sevilla
María Belen Noboa-Sevilla
GAGabriela J. Acosta-García
Gabriela J. Acosta-García
ACAlejandro Casas
Alejandro Casas
Introducción: Las enfermedades respiratorias crónicas generan una discapacidad compleja vinculada a la inactividad física progresiva, los efectos sistémicos y el impacto emocional, deteriorando la calidad de vida y aumentando la utilización de servicios sanitarios. La rehabilitación respiratoria (RR) es una intervención eficaz que mejora la capacidad funcional, reduce las exacerbaciones y favorece una mejor calidad de vida. No obstante, en América Latina persisten barreras significativas que limitan su acceso y generan una implementación desigual en la región. Métodos: Un equipo multidisciplinario elaboró recomendaciones basadas en evidencia para la implementación de programas de RR. Se formularon preguntas PICO y se realizó una revisión sistemática, siguiendo la declaración PRISMA. La calidad de la evidencia se evaluó mediante el sistema GRADE. Un panel de expertos efectuó una revisión externa independiente para asegurar la validez, la rigurosidad metodológica y la aplicabilidad clínica de las recomendaciones. Resultados: Se definieron diez recomendaciones, entre ellas educación y automanejo, uso adecuado de oxígeno, fisioterapia respiratoria, telerehabilitación, terapias complementarias, abordaje psicológico, evaluación nutricional, estrategias para poblaciones en altura y entrenamiento de músculos inspiratorios. Estas intervenciones favorecen la mejora de la calidad de vida y la capacidad funcional, aumentan la adherencia terapéutica y reducen exacerbaciones. Conclusión: La RR debe integrarse como parte del tratamiento estándar en todos los niveles de atención mediante equipos multidisciplinarios capacitados. Este consenso unifica criterios regionales y apoya la expansión de programas de RR seguros, efectivos y sostenibles, adaptados a las necesidades y realidades de América Latina.

1 December 2025 in Respirar
Verified
Journal Article
Open access
PDF file
SVSara Vargas
Sara Vargas
MJMayra Castillo Jurado
Mayra Castillo Jurado
MNMaría Belen Noboa-Sevilla
María Belen Noboa-Sevilla
CECarlos Encalada
Carlos Encalada
GGGabriela García
Gabriela García
Jacobo Sellares TorresJacobo Sellares Torres
Jacobo Sellares Torres
Introduction: Interstitial lung disease (ILD) is a common and high-impact manifestation in patients with systemic autoimmune rheumatic diseases (SARDs). Timely detection requires clinical tools based on evidence and multidisciplinary consensus. Methods: A multidisciplinary team developed the consensus for the screening and diagnosis of ILD-SARDs through the formulation of PICO clinical questions, a systematic literature review (2017–2023) reported in accordance with the PRISMA statement, evaluation of the evidence using the GRADE system, and the formulation of clinical practice recommendations, which were validated using the Delphi methodology. Results: Twelve key recommendations were established for the screening and diagnosis of interstitial lung disease (ILD) in patients with Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE), Sjögren’s Syndrome (SS), Mixed Connective Tissue Disease (MCTD) and Idiopathic Inflammatory Myopathies (IIM). The use of high-resolution computed tomography (HRCT) and pulmonary function tests is highlighted as fundamental diagnostic tools. Respiratory assessment is recommended at each visit, along with active surveillance of fibrotic progression risk in diagnosed patients. Routine lung biopsy is not suggested, except in cases of suspected malignancy or discordant diagnoses. Conclusion: The implementation of evidence-based recommendations for the screening and diagnosis of ILD-SARDs aims to improve early detection, multidisciplinary intervention and patient prognosis. Their adoption can help standardize clinical practices and optimize care across all levels of the healthcare system.